Keeping Track: Immunocore Wins Nod For First T-Cell Receptor Therapeutic; Veklury And Nucala Expand Settings Of Use; Merck & Co. Strikes Out In Chronic Cough
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Merck’s Gefapixant: FDA Questions Whether Small Reduction In Chronic Cough Is Clinically Meaningful
Gefapixant 45 mg had a 15% to 17% relative reduction in 24-hour cough frequency compared to placebo from baseline to week 24 or week 12. Advisory committee to vote on whether this decrease along with results from patient-reported outcomes demonstrate a clinically meaningful benefit.
Japan Lifts Decades-Old Bans On Somatropin In Diabetes, IFNβ In Pregnancy
Japan cautiously lifts decades-old bans on somatropin’s use in diabetic patients and interferon beta 1a/1b in pregnant patients, judging benefits can outweigh risks and following requests from doctors and pharma firms to consider patients.
J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark
Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming and new updates from multiple Asian companies.